Carl D. Regillo, MD, FACS

John W Kitchens, MD, bookends the discussion by highlighting the landscape of branch vein occlusion (BRVO) treatment options.

Dante J Pieramici, MD, shifts the conversation to diabetic macular edema (DME) and the promising drying and anatomical results from an open-label long-term extension trial.

Margaret A Chang, MD, MS, discusses efficacy and safety results of faricimab for neovascular age-related macular degeneration (nAMD) treatments.

Carl D Regillo, MD, FACS, begins the discussion highlighting each disease state and the landscape of treatment.

Retina specialists share advice and practice pearls regarding the management of DME and neovascular AMD, including counseling patients about the importance of healthy lifestyles.

Carl D. Regillo, MD, FACS, leads a discussion with retina specialists about the future of care for AMD and DME, including tyrosine kinase inhibition and gene therapy.

Retina specialists discuss concerns and apprehensions that both physicians and patients may feel towards newer modalities and delivery mechanisms for the treatment of AMD and DME.

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, talk about important data that has awaited for several newer and investigational therapies for DME and AMD.

Carl D. Regillo, MD, FACS, and Michael A. Klufas, MD, discuss the possible impact of biosimilars and share important considerations regarding cost and safety.

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, consider the utility of a novel port delivery system for the delivery of anti-VEGF treatment.

Thought leaders review the clinical and practical implications of a novel port delivery system for the treatment of neovascular age-related macular degeneration [AMD].

Michael A. Klufas, MD, reviews the design and key findings from clinical trials for faricimab.

Carl D. Regillo, MD, FACS; and David R. Lally, MD, discuss the recent FDA approval of faricimab and the potential impact of having a molecule that inhibits 2 pathways that play a role in diabetic macular edema and neovascularization in the treatment armamentarium.

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, consider the implications of real-world evidence indicating fewer visual gains associated with anti-VEGF therapies compared with clinical trials.

Dr Regillo leads a discussion with retina specialists about the utility and limitations of anti-VEGF agents in the treatment of patients with AMD and DME.

Dr Regillo, Dr Cooper, and Dr Klufas emphasize the importance of a personalized approach and share strategies for assessing outcomes in patients with AMD and DME.

A panel of retina specialists discuss how to balance durability, visual acuity, and other factors when selecting the appropriate regimen for patients with AMD and DME.

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, share guidance on how to initiate conversations with patients who have been diagnosed with AMD or DME.

Carl D. Regillo, MD, FACS; Blake Anthony Cooper, MD, MPH; Michael A. Klufas, MD; and David R. Lally, MD, review the clinical benefits of early detection of AMD and DME.

Carl D. Regillo, MD, FACS; Michael A. Klufas, MD; and David R. Lally, MD, discuss how increasing awareness regarding AMD and DME among patients and the medical community may lead to early treatment interventions.